scholarly journals Interferon-Induced Transmembrane Protein 1 (IFITM1) Promotes Distant Metastasis of Small Cell Lung Cancer

2020 ◽  
Vol 21 (14) ◽  
pp. 4934
Author(s):  
Shuichi Sakamoto ◽  
Hiroyuki Inoue ◽  
Yasuko Kohda ◽  
Shun-ichi Ohba ◽  
Taketoshi Mizutani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Transmembrane Protein ◽  
Small Cell ◽  
Small Cell Lung ◽  
Orthotopic Model ◽  
Metastatic Tumors ◽  
Metastatic Sites

Small cell lung cancer (SCLC) is a severe malignancy associated with early and widespread metastasis. To study SCLC metastasis, we previously developed an orthotopic transplantation model using the human SCLC cell line DMS273. In the model, metastatic foci were found in distant tissues such as bone and the adrenal gland, similarly as observed in patients with SCLC. In this study, we evaluated the differentially expressed genes between orthotopic and metastatic tumors in the model. We isolated tumor cells from orthotopic and metastatic sites, and the tumor cell RNA was analyzed using DNA microarray analysis. We found that 19 genes in metastatic tumors were upregulated by more than 4-fold compared with their expression in orthotopic tumors. One of these genes encodes a transmembrane protein, interferon (IFN)-induced transmembrane protein 1 (IFITM1), and immunohistochemical analysis confirmed the higher expression of the protein in metastatic sites than in orthotopic sites. IFITM1 was also detected in some SCLC cell lines and lung tumors from patients with SCLC. The overexpression of IFITM1 in DMS273 cells increased their metastatic formation in the orthotopic model and in an experimental metastasis model. Conversely, the silencing of IFITM1 suppressed metastatic formation by DMS273 cells. We also found that IFITM1 overexpression promoted the metastatic formation of NCI-H69 human SCLC cells. These results demonstrate that IFITM1 promotes distant metastasis in xenograft models of human SCLC.

Yield of Total Body GA-67 Scintigraphy in the Staging of Non-Small Cell Lung Cancer

1989 ◽  
Vol 75 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Gianfranco Buccheri ◽  
Ferruccio Vola ◽  
Domenico Ferrigno ◽  
Antonio Curcio
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
False Negative ◽  
Small Cell ◽  
Whole Body ◽  
Small Cell Lung ◽  
Mediastinal Disease ◽  
Metastatic Sites ◽  
Sensitivity Specificity

One hundred and one patients with histologically proved non-small cell lung cancer underwent whole body gallium-67 (TB Ga-67) scintigraphy as a part of their routine pretreatment evaluation. Twenty-eight of these patients were subsequently operated and pathologically staged for hilar and mediastinal disease. Two other patients underwent mediastinoscopy, but were judged unresectable at that time. All had computed tomography (CT) of the thorax, as well as radionuclide or CT scans of suspicious metastatic areas, and were carefully followed-up. When possible, a biopsy was performed of each suspected metastasis. Primary lung tumors concentrated Ga-67 in 94 patients. Sensitivity, specificity, and accuracy for hilar and mediastinal node metastases were 58%, 89%, and 77%, respectively. There were no false-negative gallium scans as regards secondary involvement of both liver and bone, whereas only 1 of the 4 brain metastases was detected by the technique. Sensitivity, specificity, and accuracy for all metastatic sites were 82%, 38%, and 56%, respectively. Fifty-five patients were classified as having a more advanced stage of disease by TB Ga-67 scintigraphy than at the initial clinical evaluation. However, 42 gallium-staged patients were ultimately re-classified differently according to all available clinical data. Using TB Ga-67 scintigraphy, 21 patients were found to have occult metastases which would not otherwise have been recognized; for the above reason, an unnecessary intervention was avoided in 6 of them.

Thallium-201 SPECT in advanced non-small cell lung cancer: In relation with chemotherapeutic response, survival, distant metastasis and p53 status

2003 ◽  
Vol 17 (5) ◽  
pp. 369-374 ◽  
Author(s):  
Tevfik Fikret Çermik ◽  
Mahmut Yüksel ◽  
Celal Karlikaya ◽  
Latife Doĝanay ◽  
Mevlüt Türe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Thallium 201 ◽  
Small Cell Lung ◽  
Chemotherapeutic Response ◽  
P53 Status

scholarly journals Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites

2009 ◽  
Vol 4 (10) ◽  
pp. 1212-1220 ◽  
Author(s):  
Carlos Gomez-Roca ◽  
Christophe M. Raynaud ◽  
Frederique Penault-Llorca ◽  
Olaf Mercier ◽  
Frederic Commo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Differential Expression ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Metastatic Sites

scholarly journals Assessment of surgical treatment for distant metastasis from completely resected non-small cell lung cancer

2007 ◽  
Vol 21 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Tohru Hasumi ◽  
Nobuyuki Sato ◽  
Shinichirou Ohta ◽  
Masami Sato ◽  
Chiaki Endo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Effects of Vasculogenic Mimicry on Postoperative Recurrence and Progression of Non-Small Cell Lung Cancer

2021 ◽  
Vol 5 (4) ◽  
pp. 81-92
Author(s):  
Baoyong Ling ◽  
Aiqin Peng ◽  
Jijun You ◽  
Zhisheng Zhang ◽  
Weichun Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Local Recurrence ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Vasculogenic Mimicry ◽  
Postoperative Recurrence ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Vasculogenic mimicry (VM) in lung cancer shortens overall survival (OS) but its’ associations with postoperative recurrence and progression of early non-small cell lung cancer (NSCLC) remain unclear. The purpose of this study was to analyze the association of VM with postoperative recurrence and progression of NSCLC as well as the effect of VM on postoperative recurrence-free survival (RFS). This study included NSCLC patients and detected VM in surgical specimens. The associations of VM with the recurrence and progression were analyzed to assess the effect of VM on postoperative RFS in NSCLC. A total of 80 NSCLC cases were followed up for 3 years. During follow-up, 35 cases showed recurrence and progression where 5 (6.25%) cases had simple local recurrence and the other 30 (37.5%) cases had distant metastasis. The recurrence and progression rates in the first, second, and third years were 12.50%, 23.75%, and 7.50%, respectively. The median RFS was 14.2 months. VM was detected in 30 out of 80 cases and was significantly correlated with tumor differentiation (r = 0.365) and clinical stage (r = 0.374) (both, P = 0.001). Local recurrence of NSCLC was not correlated with VM, unlike distant metastasis (r = 0.598, P < 0.001). Average RFS was significantly longer in NSCLC patients without VM compared with the VM group 3 years post-operation (32 months versus 18 months, log-rank test P < 0.001). Considering these, VM is significantly correlated with postoperative distant metastasis of NSCLC in which it is of a certain value for predicting poor prognosis in NSCLC.

Sign in / Sign up

Export Citation Format

Share Document